Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -94.99% | -8.64% | |||
| Gross Profit | 94.99% | 8.64% | |||
| SG&A Expenses | -7.90% | 11.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.28% | -2.23% | |||
| Operating Income | 10.28% | 2.23% | |||
| Income Before Tax | -38.58% | 7.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.58% | 7.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.58% | 7.10% | |||
| EBIT | 10.28% | 2.23% | |||
| EBITDA | 9.88% | 2.23% | |||
| EPS Basic | -38.48% | 19.80% | |||
| Normalized Basic EPS | 11.23% | 19.82% | |||
| EPS Diluted | -38.48% | 20.34% | |||
| Normalized Diluted EPS | 11.23% | 19.82% | |||
| Average Basic Shares Outstanding | 0.06% | 15.86% | |||
| Average Diluted Shares Outstanding | 0.06% | 15.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||